XML 75 R45.htm IDEA: XBRL DOCUMENT
v3.24.0.1

REVENUE RECOGNITION (Details) - USD ($) $ in Thousands |  | 4 Months Ended | 12 Months Ended |
--- | --- | --- | --- | ---
Jul. 13, 2022 | Dec. 31, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2014
Revenue Recognition and Collaborative Arrangements |  |  |  |  |  |
Total net revenue |  |  | $ 310,463 | $ 331,339 | $ 391,866 |
Milestone fees paid |  | $ 220,000 | 220,000 | 220,000 |  |
United States |  |  |  |  |  |
Revenue Recognition and Collaborative Arrangements |  |  |  |  |  |
Milestone fees paid |  | 120,000 | $ 120,000 | 120,000 |  |
Net Product Sales | Geographic Concentration Risk | United States |  |  |  |  |  |
Revenue Recognition and Collaborative Arrangements |  |  |  |  |  |
Concentration Risk, Percentage |  |  | 91.00% |  |  |
Net Product Sales | Geographic Concentration Risk | Rest of the world |  |  |  |  |  |
Revenue Recognition and Collaborative Arrangements |  |  |  |  |  |
Concentration Risk, Percentage |  |  | 9.00% |  |  |
Royalty revenue |  |  |  |  |  |
Revenue Recognition and Collaborative Arrangements |  |  |  |  |  |
Total net revenue |  |  | $ 238,846 | 311,645 | 391,866 |
GIAPREZA |  |  |  |  |  |
Revenue Recognition and Collaborative Arrangements |  |  |  |  |  |
Total net revenue |  |  | 41,300 |  |  |
XERAVA |  |  |  |  |  |
Revenue Recognition and Collaborative Arrangements |  |  |  |  |  |
Total net revenue |  |  | 17,300 |  |  |
XACDURO |  |  |  |  |  |
Revenue Recognition and Collaborative Arrangements |  |  |  |  |  |
Total net revenue |  |  | 2,000 |  |  |
GSK |  |  |  |  |  |
Revenue Recognition and Collaborative Arrangements |  |  |  |  |  |
Percentage of royalty payments not entitled to receive | 15.00% |  |  |  |  |
Total net revenue |  |  | $ 238,846 | $ 311,645 | $ 391,866 |
GSK | Long-Acting Beta2 Agonist (LABA) Collaboration |  |  |  |  |  |
Revenue Recognition and Collaborative Arrangements |  |  |  |  |  |
Milestone fees paid |  |  |  |  |  | $ 220,000
Percentage of economic interest in any future payments made under the agreements |  |  | 15.00% |  |  |
GSK | RELVAR/BREO | Long-Acting Beta2 Agonist (LABA) Collaboration |  |  |  |  |  |
Revenue Recognition and Collaborative Arrangements |  |  |  |  |  |
Royalty rate for first level of annual global net sales (as a percent) |  |  | 15.00% |  |  |
Annual global sales level used to determine royalty rate |  |  | $ 3,000,000 |  |  |
Royalty rate for sales above first level of annual global net sales (as a percent) |  |  | 5.00% |  |  |
GSK | ANORO | Long-Acting Beta2 Agonist (LABA) Collaboration | Minimum |  |  |  |  |  |
Revenue Recognition and Collaborative Arrangements |  |  |  |  |  |
Royalty rate for combination products (as a percent) |  |  | 6.50% |  |  |
GSK | ANORO | Long-Acting Beta2 Agonist (LABA) Collaboration | Maximum |  |  |  |  |  |
Revenue Recognition and Collaborative Arrangements |  |  |  |  |  |
Royalty rate for combination products (as a percent) |  |  | 10.00% |  |  |
GSK | TRELEGY | Long-Acting Beta2 Agonist (LABA) Collaboration | Minimum |  |  |  |  |  |
Revenue Recognition and Collaborative Arrangements |  |  |  |  |  |
Royalty rate for combination products (as a percent) |  |  | 6.50% |  |  |
GSK | TRELEGY | Long-Acting Beta2 Agonist (LABA) Collaboration | Maximum |  |  |  |  |  |
Revenue Recognition and Collaborative Arrangements |  |  |  |  |  |
Royalty rate for combination products (as a percent) |  |  | 10.00% |  |  |
La Jolla |  |  |  |  |  |
Revenue Recognition and Collaborative Arrangements |  |  |  |  |  |
Total net revenue |  | $ 19,700 | $ 60,600 |  |  |
La Jolla | Net Product Sales | Geographic Concentration Risk | United States |  |  |  |  |  |
Revenue Recognition and Collaborative Arrangements |  |  |  |  |  |
Concentration Risk, Percentage |  | 96.00% |  |  |  |
La Jolla | Net Product Sales | Geographic Concentration Risk | Rest of the world |  |  |  |  |  |
Revenue Recognition and Collaborative Arrangements |  |  |  |  |  |
Concentration Risk, Percentage |  | 4.00% |  |  |  |
La Jolla | GIAPREZA |  |  |  |  |  |
Revenue Recognition and Collaborative Arrangements |  |  |  |  |  |
Total net revenue |  | $ 14,200 |  |  |  |
La Jolla | XERAVA |  |  |  |  |  |
Revenue Recognition and Collaborative Arrangements |  |  |  |  |  |
Total net revenue |  | $ 5,500 |  |  |  |

X
- Definition Represents the royalty rate for combination products. + References No definition available. + Details
Name: | inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts
Namespace Prefix: | inva_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the royalty rate which the entity will receive under the collaboration agreement on the first defined level of annual global net sales. + References No definition available. + Details
Name: | inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne
Namespace Prefix: | inva_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the royalty rate which the entity will receive under the collaboration agreement on sales which exceed the first defined level of annual global net sales. + References No definition available. + Details
Name: | inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo
Namespace Prefix: | inva_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the annual global net sales amount which determines the royalty rate applied under the collaboration arrangement. + References No definition available. + Details
Name: | inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate
Namespace Prefix: | inva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the percentage of economic interest in any future payments made under the agreements. + References No definition available. + Details
Name: | inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements
Namespace Prefix: | inva_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of royalty payments the company is not entitled to receive. + References No definition available. + Details
Name: | inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive
Namespace Prefix: | inva_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3 + Details
Name: | us-gaap_CapitalizedContractCostGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_RoyaltyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=inva_GiaprezaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=inva_XeravaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=inva_XacduroMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=inva_LabaCollaborationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistRelvarBreoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistAnoroMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=inva_TrelegyElliptaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_LaJollaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |